Literature DB >> 31672450

Moderate and heavy alcohol consumption are prospectively associated with decreased left ventricular ejection fraction: The Hoorn Study.

Sabine van Oort1, Joline W Beulens2, Amber A W A van der Heijden3, Petra J M Elders3, Coen D A Stehouwer4, Inge A T van de Luitgaarden5, Ilse C Schrieks5, Diederick E Grobbee5, Adriana J van Ballegooijen6.   

Abstract

BACKGROUND AND AIMS: Data on the prospective relationship of alcohol consumption at more moderate levels with systolic and diastolic function are scarce. We aimed to examine the prospective association of alcohol consumption with echocardiographic measures of cardiac structure and function, in individuals with and without type 2 diabetes (T2DM). METHODS AND
RESULTS: We included 778 participants from the Hoorn Study (aged 68.4 ± 7.2 years, 49% women), a population-based prospective cohort study, oversampled for people with impaired glucose metabolism or T2DM. Self-reported alcohol consumption was collected at baseline with a validated food-frequency questionnaire and categorized into: none (0/week), light (>0-≤30 g/week), light-to-moderate (>30-≤70 g/week), moderate (>70-≤140 g/week), and heavy drinkers (>140 g/week). Echocardiography was performed at baseline (N = 778) and after 8 years follow-up (N = 404). Multiple linear regression was used to study the association between alcohol consumption and echocardiographic measures (left ventricular ejection fraction (LVEF), left atrial volume index (LAVI) and left ventricular mass index (LVMI)), adjusted for confounders. Moderate and heavy alcohol consumption were associated with a decreased LVEF of -3.91% (CI: -7.13;-0.69) for moderate and -4.77% (-8.18;-1.36) for heavy drinkers compared to light drinkers. No associations were found between alcohol consumption, LVMI and LAVI. Modified Poisson regression showed a trend that higher alcohol consumption amounts were associated with a higher risk of incident systolic dysfunction (LVEF≤50%) (P-for-trend 0.058).
CONCLUSION: The findings provide longitudinal evidence that moderate and heavy alcohol consumption are associated with decreased LVEF and trend towards a higher risk of incident LV systolic dysfunction, compared to light drinkers.
Copyright © 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcohol consumption; Echocardiography; Epidemiology; Glucose metabolism disorders; Heart failure; Life style

Mesh:

Year:  2019        PMID: 31672450     DOI: 10.1016/j.numecd.2019.09.021

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  4 in total

1.  A systematic review of self-report measures used in epidemiological studies to assess alcohol consumption among older adults.

Authors:  Kjerstin Tevik; Sverre Bergh; Geir Selbæk; Aud Johannessen; Anne-S Helvik
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

2.  Alcohol consumption in the general population is associated with structural changes in multiple organ systems.

Authors:  Hideaki Suzuki; Wenjia Bai; Evangelos Evangelou; Raha Pazoki; He Gao; Paul M Matthews; Paul Elliott
Journal:  Elife       Date:  2021-06-01       Impact factor: 8.713

3.  Heavy alcohol drinking and subclinical echocardiographic abnormalities of structure and function.

Authors:  Olena Iakunchykova; Henrik Schirmer; Darryl Leong; Sofia Malyutina; Andrew Ryabikov; Maria Averina; Alexander Kudryavtsev; Mikhail Kornev; Ekaterina Voronina; Andrey Paramonov; Tom Wilsgaard; David Leon
Journal:  Open Heart       Date:  2021-06

4.  miR-155-5p upregulation ameliorates myocardial insulin resistance via mTOR signaling in chronic alcohol drinking rats.

Authors:  Zhaoping Li; Zhenzhen Hu; Yan Meng; Hongzhao Xu; Yali Wei; Deqiang Shen; Hao Bai; Huacai Yuan; Liyong Chen
Journal:  PeerJ       Date:  2021-04-05       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.